• NeOnc reported early clinical improvement in its first child treated with investigational intranasal NEO100 under compassionate use in Abu Dhabi.
• The critically ill three-year-old boy with an aggressive brain tumor is breathing without ventilator support, beginning to move his legs.
• Treatment occurred outside the NEO100-03 pediatric trial because the child did not meet eligibility criteria.
• These single-patient observations do not establish treatment benefit; pediatric safety and efficacy remain unproven.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-011446), on October 22, 2026, and is solely responsible for the information contained therein.